163 related articles for article (PubMed ID: 38103099)
21. Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.
Takaishi K; Tsukamoto S; Ohwada C; Takeuchi M; Kawasaki Y; Nagai Y; Mishina T; Yamazaki M; Isshiki Y; Kayamori K; Kimura K; Hino Y; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Iseki T; Nakaseko C; Sakaida E
J Thromb Thrombolysis; 2019 Jul; 48(1):141-148. PubMed ID: 30673940
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
23. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
[TBL] [Abstract][Full Text] [Related]
25. Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy.
Dede RJ; Pruemer JM
J Oncol Pharm Pract; 2016 Apr; 22(2):248-55. PubMed ID: 25632017
[TBL] [Abstract][Full Text] [Related]
26. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Covut F; Ahmed R; Chawla S; Ricaurte F; Samaras CJ; Anwer F; Garcia AVM; Angelini DE; Mazzoni S; Faiman B; Valent J; Khouri J
Br J Haematol; 2021 Jun; 193(6):1213-1219. PubMed ID: 33997961
[TBL] [Abstract][Full Text] [Related]
27. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D; Sergentanis TN; Papageorgiou L; Stamatelopoulos K; Gavriatopoulou M; Kastritis E; Psaltopoulou T; Salta S; Van Dreden P; Sangare R; Larsen AK; Terpos E; Elalamy I; Dimopoulos MA; Gerotziafas GT
Blood Cancer J; 2018 Nov; 8(11):102. PubMed ID: 30405097
[TBL] [Abstract][Full Text] [Related]
28. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
29. The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients.
Beauchamp-Chalifour P; Belzile ÉL; Michael R; Langevin V; Gaudreau N; Normandeau N; Bédard L; Pelet S
Orthop Traumatol Surg Res; 2022 Feb; 108(1):103142. PubMed ID: 34775033
[TBL] [Abstract][Full Text] [Related]
30. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Baljevic M; Sborov DW; Lim MY; Hillengass J; Martin T; Castillo JJ; Streiff MB; Kumar SK; Callander NS
J Natl Compr Canc Netw; 2022 Jan; 20(1):91-95. PubMed ID: 34991076
[TBL] [Abstract][Full Text] [Related]
31. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Chalayer E; Talbot A; Frenzel L; Karlin L; Collet P; Guyotat D; Attal M; Leleu X; Tardy B
J Thromb Haemost; 2022 Aug; 20(8):1859-1867. PubMed ID: 35557490
[TBL] [Abstract][Full Text] [Related]
32. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
Swan D; Rocci A; Bradbury C; Thachil J
Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
[TBL] [Abstract][Full Text] [Related]
33. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Carrier M; Le Gal G; Tay J; Wu C; Lee AY
J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
[TBL] [Abstract][Full Text] [Related]
34. A review of the venous thrombotic issues associated with multiple myeloma.
Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
[TBL] [Abstract][Full Text] [Related]
35. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
36. Venous thromboembolism in the hematologic malignancies.
Falanga A; Marchetti M; Russo L
Curr Opin Oncol; 2012 Nov; 24(6):702-10. PubMed ID: 23014188
[TBL] [Abstract][Full Text] [Related]
37. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
Li A; Wu Q; Luo S; Warnick GS; Zakai NA; Libby EN; Gage BF; Garcia DA; Lyman GH; Sanfilippo KM
J Natl Compr Canc Netw; 2019 Jul; 17(7):840-847. PubMed ID: 31319391
[TBL] [Abstract][Full Text] [Related]
38. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
Covut F; Sanfilippo KM
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of the predictive value of Padua and the IMPEDE assessment scores for venous thromboembolism in patients with newly diagnosed multiple myeloma: A single institution experience].
Fang LJ; Yao XD; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Chen Y; Wang MZ; Zhao X; Hu WK; Sun K; Bao L
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):395-400. PubMed ID: 37550189
[No Abstract] [Full Text] [Related]
40. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.
Wun T; White RH
Thromb Res; 2010 Apr; 125 Suppl 2():S96-102. PubMed ID: 20434017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
